Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.48
-0.1500-4.13%
Post-market: 3.490.0100+0.29%18:48 EDT
Volume:6.29M
Turnover:22.12M
Market Cap:1.14B
PE:-2.71
High:3.68
Open:3.66
Low:3.48
Close:3.63
Loading ...

Iovance Biotherapeutics Inc: Q4 Shr Loss $0.26

THOMSON REUTERS
·
28 Feb

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

GlobeNewswire
·
28 Feb

Iovance Biotherapeutics options imply 12.4% move in share price post-earnings

TIPRANKS
·
28 Feb

What's in Store for These 5 Biotech Stocks This Earnings Season?

Zacks
·
24 Feb

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
22 Feb

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

GlobeNewswire
·
19 Feb

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
18 Feb

Iovance Biotherapeutics call volume above normal and directionally bullish

TIPRANKS
·
15 Feb

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
13 Feb

Iovance Biotherapeutics appoints Kirby as Chief Commercial Officer

TIPRANKS
·
10 Feb

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

GlobeNewswire
·
10 Feb

Iovance Biotherapeutics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
31 Jan

Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler

TIPRANKS
·
31 Jan

Truist Financial Releases a Buy Rating on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
30 Jan

Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment

TIPRANKS
·
28 Jan

Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics

Simply Wall St.
·
24 Jan